Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy

Abstract EN

Background.

Sensory neuropathy (SN) is one of the most common AIDS-associated neurologic disorders especially in the era of highly active antiretroviral therapy (HAART).

The aim of this study was to determine the prevalence of SN among highly-active-antiretroviral-therapy- (HAART-) experienced and HAART-naïve HIV-positive individuals and to investigate the relationship to demographic, clinical, and laboratory factors.

Methods.

323 patients with HIV infection (142 on HAART and 181 HAART naïve) were enrolled in a cross-sectional neuropathy screening program.

Data was collected using structured questionnaires which contained the brief peripheral neuropathy screening tool of AIDS Clinical Trial Group protocol.

Neuropathy was defined by the presence of at least 1 clinical sign in a distal, symmetrical pattern.

Patients were classified as symptomatic if they described aching, stabbing, or burning pain, paresthesia, or numbness in a similar distribution.

Demographic, clinical, and laboratory details were documented as risk factors.

Result.

The prevalence of sensory neuropathy was 39.0% (126/323), (of which 29/126 (23%)) were symptomatic.

Amongst those on HAART, 60/142 (42.3%) had SN compared to 66/181 (36.5%) HAART-naïve individuals (P=0.29).

On multivariate analyses, the independent associations with SN were increasing age (P=0.03) and current exposure to stavudine (P=0.00).

Gender (P=0.99) height (P=0.07) use of HAART (P=0.50), duration of HAART treatment (P=0.10), and lower CD4 count (P=0.12) were not associated with an increased SN risk.

Conclusion.

HIV SN remains common despite improved immunologic function associated with HAART and decreased neurotoxic HAART use.

In this cross-sectional analysis, age and stavudine-based therapies were the independent risk factors.